SEP-225289 News
Most Popular SEP-225289 Story
Sepracor depression drug flunks a mid-stage test
Sepracor ran into an unexpected setback on a mid-stage therapeutic for depression. Researchers say that the drug--SEP-225289--failed to deliver positive data in a trial that dosed 514 patients over Read more...
Latest Headlines
- July 2, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
